DelveInsight’s, “Acute Pain Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Pain Research. Learn more about our innovative pipeline today! @ Acute Pain Pipeline Outlook

Key Takeaways from the Acute Pain Pipeline Report

• In April 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
• In April 2025, Latigo Biotherapeutics conducted a phase 2 dose-ranging study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars.
• DelveInsight’s Acute Pain Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Pain treatment.
• The leading Acute Pain Companies such as Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc. and others.
• Promising Acute Pain Pipeline Therapies such as Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.

Stay informed about the cutting-edge advancements in Acute Pain treatments. Download for updates and be a part of the revolution in neurology care @ Acute Pain Clinical Trials Assessment

Acute Pain Emerging Drugs Profile

• NTM-001: Neumentum

NTM-001 is Neumentum’s lead product candidate: a novel, alcohol-free formulation of the powerful NSAID ketorolac, in a pre-mixed bag designed for 24-hours of continuous infusion following surgery. It is being evaluated to manage moderately severe acute pain that requires analgesia at the opioid-level, usually in a postoperative setting.

• CGT 1507: CGeneTech

Otenaproxesul is a novel nonsteroidal anti-inflammatory drug (“NSAID”) that releases hydrogen sulfide. Antibe is leveraging the drug’s remarkable potency, gastrointestinal (“GI”) protection and overall safety profile for use in acute pain indications. Otenaproxesul, is being developed as a safer non-opioid analgesic for post-operative pain.

• TRPA1 Antagonist: Algomedix

Algomedix is developing a non-opioid, non-addictive, novel TRPA1 antagonist for the treatment of acute and chronic pain. Algomedix is focused on the advancement of a novel, small molecule TRPA1 antagonist for the treatment of pain. This clinical candidate offers the potential for a next-generation analgesic devoid of the addiction and abuse liabilities, as well as other adverse effects inherent in the opioid class of drugs.

Acute Pain Market Drivers

• Increasing demand for long-term pain management among the geriatric population
• Government investments for healthcare interoperability

Acute Pain Market Barriers

• The availability of alternate pain management systems
• Side-effects associated with the disease

Learn more about Acute Pain Drugs Opportunities in our groundbreaking Acute Pain Research and development projects @ Acute Pain Unmet Needs

The Acute Pain pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Pain with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Pain Treatment.
• Acute Pain Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Pain market.

Acute Pain Companies

Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc. and others

Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Acute Pain Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Acute Pain treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Acute Pain Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Pain Pipeline Report

• Coverage- Global
• Acute Pain Companies- Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc. and others.
• Acute Pain Pipeline Therapies- Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.
• Acute Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase II

For a detailed overview of our latest research findings and future plans, read the full details of Acute Pain Pipeline on our website @ Acute Pain Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Acute Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Pain– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. NTM-001: Neumentum
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name : Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. TRPA1 Antagonist: Algomedix
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute Pain Key Companies
21. Acute Pain Key Products
22. Acute Pain- Unmet Needs
23. Acute Pain- Market Drivers and Barriers
24. Acute Pain- Future Perspectives and Conclusion
25. Acute Pain Analyst Views
26. Acute Pain Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-pain-pipeline-insight